KRTL Holding Group, Inc. and Aura Nootropics Advance Thailand-Focused Methylene Blue Initiative

About this update from Krtl Holding Group, Inc

KRTL Holding Group, Inc. (“KRTL Holding” or the “Company”) announced today that its subsidiary, KRTL Biotech Inc. (“KRTL Biotech”), and Aura Nootropics, Inc. (“AURA”) are continuing to advance their previously announced strategic collaboration relating to methylene blue-based consumer product opportunities beginning in Thailand. Following the Parties’ recently announced partnership framework, KRTL Biotech and AURA are now coordinating operational, regulatory, and commercial evaluation efforts relating to potential methylene blue (“MB”) product applications in international consumer markets. The Parties are currently evaluating potential pathways for the lawful importation, formulation integration, and commercialization of methylene blue-based products, subject to applicable regulatory requirements, product classification review, manufacturing standards, labeling requirements, and any additional agreements that may be required. As part of these efforts, KRTL Biotech and AURA are also assessing regional manufacturing, supply-chain, and production opportunities within Thailand to support scalability, operational efficiency, and long-term commercial viability as the initiative develops. The collaboration continues to combine KRTL Biotech’s access to a proprietary methylene blue formulation and regulatory positioning with AURA’s established network in Thailand and experience in product development, branding, distribution strategy, and market access. The Company indicated that Thailand is expected to serve as an initial strategic market for evaluating product development and commercialization opportunities, with broader regional expansion opportunities to be considered as the collaboration progresses. Leadership of KRTL Biotech Inc. stated, “Following the establishment of our strategic relationship with AURA, our focus is now centered on evaluating the operational and regulatory framework necessary to support future commercialization opportunities. AURA’s market knowledge, product-development capabilities, and relationships in Thailand provide an important foundation as we work to assess appropriate pathways for product integration, importation, manufacturing, and long-term market development.” KRTL Holding stated that the initiative reflects its broader strategy of advancing biotechnology and consumer health opportunities through disciplined product evaluation, regulatory alignment, strategic partnerships, and international market development.   About KRTL Holding Group Inc. KRTL Holding Group Inc. is focused on advancing innovation across biotechnology, pharmaceuticals, and emerging healthcare platforms through its subsidiaries, including KRTL Biotech Inc. and KRTL International. About KRTL Biotech Inc. KRTL Biotech Inc. is focused on the development and commercialization of specialized compounds and biotechnology-driven solutions, with an emphasis on regulatory-aligned applications across pharmaceutical, nutraceutical, and consumer markets. About Aura Nootropics, Inc. Aura Nootropics, Inc. is focused on the development, branding, and commercialization of consumer products within the nootropic and wellness sectors.   For more information: www.krtlholding.com | www.krtl-icc.com | www.krtlbiotech.com | www.auranootropics.com   Forward-Looking Statements This press release contains statements and information that, to the extent they are not historical facts, may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include statements regarding the Company’s collaboration with Aura, the evaluation of potential methylene blue-based product opportunities, possible development or commercialization pathways, product classification and regulatory review, market access, branding, distribution, future agreements, and the Company’s broader business strategy. Forward-looking statements are based on current expectations, assumptions, estimates, and information available to management as of the date of this release. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. These risks include, without limitation, the risk that the parties may not enter into definitive agreements; that product feasibility, formulation, manufacturing, labeling, import, distribution, or regulatory requirements may not support future product activity; that required approvals, permissions, or commercial arrangements may not be obtained; that market conditions may not support the proposed opportunity; that financing may not be available on acceptable terms or at all; and other risks relating to the Company’s business, operations, and regulatory environment. Forward-looking statements are not guarantees of future performance. Readers should not place undue reliance on forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update or revise any forward-looking statements except as required by applicable law.

View stock analysis, news, and events for Krtl Holding Group, Inc